Aardvark Therapeutics, Inc. (AARD) News
Track canonical SquawkNews coverage tagged to AARD, Aardvark Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aardvark Therapeutics Price Target Maintained With a $6.00/Share by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 01:37 PM UTC
L
AARD - Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
AARD - Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
EQUITY | Aug 26, 2026, 05:31 PM UTC
L
AARD - Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Act
AARD - Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action
EQUITY | Aug 24, 2026, 01:06 PM UTC
L
AARD - LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, s
AARD - LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation
REGULATION | Aug 20, 2026, 06:34 PM UTC
L
AARD - Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
AARD - Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
EQUITY | Aug 14, 2026, 11:49 PM UTC
L
Aardvark Therapeutics Q2 EPS Beats Estimate
Aardvark Therapeutics reports Q2 EPS of $(0.66), beating the $(0.91) estimate
EARNINGS | Aug 11, 2026, 08:55 PM UTC
L
AARD Reports Q2 2026 Financial Results
Aardvark Therapeutics reports second quarter 2026 financial results and provides business updates
EARNINGS | Aug 11, 2026, 08:53 PM UTC
L
AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
EQUITY | Jun 25, 2026, 01:01 PM UTC